Ginko biloba (EGb 761) protection against HIV-associated neurological diseases

TECH FIELD(S)
Medical-Therapeutic

FEATURES HIV-1
Tat protein is an important pathogenic factor in HIV-associated neuropathogenesis although there are few therapies that have been developed to specifically target HIV infection in the brain. Researchers at Indiana University have discovered that a standardized formulation of Ginkgo biloba extract (EGb-761) possesses neuroprotective properties useful to prevent neurological damage of the type associated with HIV infections. A component of EGb-761, the bilobade terpene, was shown to possess the important neuroprotective properties.

EGb-761 was also found to cause down modulation of GFAP in a mouse model of AIDS neuropathology, resulting in reduced neurological impairment. In addition, GFAP levels were found to be an indication of the progression and effectiveness of treatment of HIV-associated neuropathogensis.

BENEFITS
Ginko biloba extract is safe and has displayed good tolerance with no adverse drug interactions Ginko biloba extract, and specifically the terpene bilobalide, protects against HIV-associated neuropathogenesis GFAP represents a new biomarker for progression and treatment of HIV-associated neuropathogenesis

Inventor(s): Johnny J. He, Ph.D.

Type of Offer: Licensing



« More Medical Patents

---